RxDoctor Payments Data

Raymond Sauls, MD

Internal Medicine · Lancaster, MANPI 1063461408

Payments from drug & device makers

$8,609in general payments, 2019–2025

Across 553 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Novo Nordisk$626
  • AbbVie$543
  • Teva Pharmaceuticals USA, Inc.$487
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,50299%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,609 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$55,293
Medicare patients
193
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$79,055
OzempicSemaglutide57$50,616
Nurtec OdtRimegepant Sulfate25$33,947
FarxigaDapagliflozin Propanediol44$33,288
XareltoRivaroxaban15$24,044
JardianceEmpagliflozin21$21,513
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$11,960
MyrbetriqMirabegron26$11,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,548
Janumet XrSitagliptin Phos/Metformin Hcl12$10,452
Spiriva RespimatTiotropium Bromide19$9,990
PremarinEstrogens, Conjugated11$5,846
Mirabegron ErMirabegron17$5,828
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$4,425
Atorvastatin Calcium281$4,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Premarin$1,387$118,847124 claims
Novo NordiskOzempic$626$50,61657 claims
AstraZenecaFarxiga$1,191$33,28844 claims
Boehringer IngelheimJardiance, Spiriva Respimat$149$31,50340 claims
Astellas Pharma US IncMyrbetriq$177$11,49026 claims
GSKTrelegy Ellipta$242$10,54813 claims
MerckJanumet Xr$77$10,45212 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$487$3,60312 claims
Scilex Pharmaceuticals Inc.Colchicine$33$1,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lancaster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →